Deanne Nixie R. Miao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Deanne Nixie R. Miao has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Britt I. Drogemoller
Department of Biochemistry and Medical Genetics, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Canada
2 shared publications - Alain Dabdoub
Department of Biological Sciences, Sunnybrook Research Institute
1 shared publication - Daniel Wilhelm Olivier
Department of Physiological Sciences, Faculty of Science, Stellenbosch University, Stellenbosch 7600, Western Cape, South Africa
1 shared publication - Feryal Ladha
Department of Biochemistry and Medical Genetics, Rady Faculty of Health Sciences University of Manitoba Winnipeg Manitoba Canada
1 shared publication - Julia M. Abitbol
Biological Sciences, Sunnybrook Research Institute Toronto Ontario Canada
1 shared publication - Samah Ahmed
Department of Biochemistry and Medical Genetics, Rady Faculty of Health Sciences University of Manitoba Winnipeg Manitoba Canada
1 shared publication
Latest Publications
- Open Access
- 5 December 2025
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 119 (4) , 846-858
Navigating the Genetic Risk of Chemotherapy‐Induced Hearing Loss in the Stria Vascularis
Cisplatin is a chemotherapy drug that causes permanent hearing loss by damaging a critical tissue lining the inner ear, called the stria vascularis (SV). Currently, the molecular mechanisms of SV damage are largely unknown and the incidence of ototoxicity in patients cannot be reliably predicted. Growing evidence suggests certain genetic variants expressed in the SV are significant risk factors for ototoxicity, which may be leveraged to better understand cisplatin‐induced hearing loss. Also highlighted are innovative developments in integrating genomic and transcriptomic data through multi‐omic approaches that may be translated to improve future genetic testing and otoprotectant development.
- 5 December 2025
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 119 (4) , 846-858
Open AccessNavigating the Genetic Risk of Chemotherapy‐Induced Hearing Loss in the Stria Vascularis
Cisplatin is a chemotherapy drug that causes permanent hearing loss by damaging a critical tissue lining the inner ear, called the stria vascularis (SV). Currently, the molecular mechanisms of SV damage are largely unknown and the incidence of ototoxicity in patients cannot be reliably predicted. Growing evidence suggests certain genetic variants expressed in the SV are significant risk factors for ototoxicity, which may be leveraged to better understand cisplatin‐induced hearing loss. Also highlighted are innovative developments in integrating genomic and transcriptomic data through multi‐omic approaches that may be translated to improve future genetic testing and otoprotectant development.
- Open Access
- 13 December 2023
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 115 (3) , 408-411
Current Perspectives on Data Sharing and Open Science in Pharmacogenomics
- 13 December 2023
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 115 (3) , 408-411
Open AccessCurrent Perspectives on Data Sharing and Open Science in Pharmacogenomics